N-Sorb Multi-Enzyme Complex (KD120 MEC)*



2017

Safety and efficacy of a novel KD120 MEC multi-enzyme complex (N-Sorb®) in human volunteers

Bernard W Downs, Steve W Kushner, Manashi Bagchi, Anand Swaroop and Debasis Bagchi

FASEB J. April 2017 31:lb312


Abstract:

Digestive enzymes have been historically consumed to enhance disintegration and dissolution of foodstuffs in the stomach. N-Sorb is a novel KD120 multi-enzyme complex (MEC) containing a range of protease, amylase, and lipase enzymes and including glucoamylase and alpha-galactosidase. Unlike conventional digestive enzymes, these enzymes are activated in pH environments ranging from 6.5 to 8.5. These enzymes are encapsulated in a patent-pending SK713 Soy Lecithin Phospholipid absorption technology (‘Prodosomes’) to facilitate rapid absorption and delivery into the blood, and increase availability to tissues. Eleven case studies from two independent clinics (one in California and one in Pennsylvania) are reported in this presentation under the strict supervision of two physicians. Eleven male and female volunteers (age: 20 to 71 years) suffering from gut related digestive problems including digestive dysfunctions and leaky gut, as well as gluten allergy, consumed a minimum of one dose (1/8 tsp Prodosomes and 1/8 tsp enzyme powder mixed into 4 ounces of water) two times per day on an empty stomach over different periods of time ranging from 1 month to 4 months. Subjects were compliant based on product usage and replacement. All subjects reported significant improvement in gastrointestinal functions among other systemic improvements. No adverse events were observed in these volunteers.


Key Points:

➢ N-Sorb enzymes are encapsulated in the patent-pending multi-lamellar clustoidal phospholipid Prodosome® architecture to facilitate rapid absorption.

➢ Unlike conventional digestive enzymes that are activated in pH ranges from 2 to 5.5, the KD120 MEC enzymes are activated in pH environments ranging from 6.5 to 8.5; i.e. in the blood and body tissues outside the GI tract.

➢ Eleven male and female volunteers (age: 20 to 71 years) suffering from gut related digestive problems, including digestive dysfunctions and leaky gut, as well as gluten allergy, consumed a minimum of one serving of N-Sorb two times per day on an empty stomach over different periods of time ranging from 1 month to 4 months

➢ All subjects reported significant improvement in gastrointestinal functions among other systemic improvements.

➢ No adverse events were observed in these volunteers.

http://www.fasebj.org/content/31/1_Supplement/lb312.abstract?sid=7a6ffc42-b8f7-4ce2-95bf-2534ade9dcfe


N-Sorb Multi-Enzyme Complex (KD120 MEC)*



2017

Sustained safety and efficacy of a novel KD120 MEC multi-enzyme complex (N-Sorb®) in human volunteers

Bernard W Downs, Steve W Kushner, Manashi Bagchi, Anand Swaroop and Debasis Bagchi

Abstract Presented at the 22nd International Conference of Functional Foods for Chronic Disease, Harvard Medical School, Boston, MA, USA, September 22-23, 2017.


Abstract:

Background: Digestive enzymes are taken with meals to enhance digestion. N-Sorb is a novel KD120 multi-enzyme complex (MEC) containing a range of protease, amylase, and lipase enzymes including glucoamylase and alpha-galactosidase. While conventional digestive enzymes are activated in a stomach pH 2-5.5, enzymes in the KD120 MEC are activated in pH environments ranging from 6.5-8.5. These enzymes are encapsulated in a patent-pending SK713 Soy Lecithin Phospholipid absorption technology (‘Prodosomes’) to achieve rapid absorption and delivery into the blood, and increase availability to tissues.

Methods: Eleven case studies (Female: 9; Male: 2, age: 20-71 years) were conducted in two independent clinics. These subjects who were suffering from a range of metabolic, neuro-immuno and GI tract related problems including leaky gut and gluten allergy, consumed a minimum of one dose (1/8 tsp Prodosomes and 1/8 tsp enzyme powder mixed into 4 ounces of water) two times per day on an empty stomach over different periods of time ranging from 1 month to 8 months with follow up (F/U) after several months. Subjects were compliant based on product usage and replacement.

Results: Clinic #1 in California: Six subjects participated in this study, and reported significant improvement in GI functions and other systemic symptoms including chronic fatigue, chronic musculoskeletal pain, leaky gut syndrome and others

Clinic #2 in Pennsylvania: Five subjects participated in this study, 4 of whom reported significant improvement in GI functions and other systemic symptoms and well-being.

Conclusions: Taking the KD120 MEC (N-Sorb), overall 10 (of 11) subjects reported significant improvement in gastrointestinal functions among other systemic improvements. Follow up after several months demonstrated sustained improvements in 9 of these volunteers with no reported adverse reactions.

Key Points:

➢ This is a follow-up evaluation on a previous study of 11 subjects from two independent clinics, suffering from a range of metabolic, neuro-immuno and GI tract related problems including leaky gut and gluten allergy.

➢ The KD120 MEC enzymes are encapsulated in a patent-pending SK713 SL Phospholipid absorption technology (‘Prodosomes’) to achieve rapid absorption and delivery into the blood, and increase availability to tissues.

➢ The subjects consumed a minimum of one dose of N-Sorb two times per day on an empty stomach over different periods of time ranging from 1 month to 8 months with follow up (F/U) after several months.

➢ Taking the KD120 MEC (N-Sorb), overall 10 (of 11) subjects reported significant improvement in gastrointestinal functions among other systemic improvements.

➢ Follow up after several months demonstrated sustained improvements with no adverse reactions in 9 of these volunteers including OCD, anger issues, brain fog, joint pain, musculoskeletal pain, depression, anxiety, fatigue; difficulty reading, writing and coordination; growth abnormalities food allergies; and GI pain among others. One subject reported no significant improvements and discontinued use of the product.

(Web Link Not Available)


1-year double blind placebo-controlled study is underway examining cardio-metabolic parameters of N-Sorb (KD120 MEC)